Soleno Therapeutics (NASDAQ:SLNO) Earns “Neutral” Rating from Cantor Fitzgerald

Soleno Therapeutics (NASDAQ:SLNO)‘s stock had its “neutral” rating reissued by Cantor Fitzgerald in a report released on Tuesday,Benzinga reports.

Several other research analysts also recently issued reports on the company. Lifesci Capital downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. HC Wainwright downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $100.00 to $53.00 in a research note on Wednesday, April 8th. Robert W. Baird lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. TD Cowen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $53.00 in a research report on Tuesday, April 7th. Finally, Zacks Research lowered shares of Soleno Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $76.67.

Soleno Therapeutics Price Performance

SLNO stock opened at $53.01 on Tuesday. The business has a 50 day simple moving average of $45.26 and a 200-day simple moving average of $45.70. The firm has a market capitalization of $2.76 billion, a PE ratio of 29.95 and a beta of -2.22. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.62 and a quick ratio of 5.32. Soleno Therapeutics has a 1 year low of $29.43 and a 1 year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. Soleno Therapeutics had a return on equity of 22.85% and a net margin of 33.70%.The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Equities research analysts anticipate that Soleno Therapeutics will post 3.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

A number of large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after acquiring an additional 189 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $25,000. Avanza Fonder AB increased its stake in shares of Soleno Therapeutics by 11.2% in the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after acquiring an additional 323 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after acquiring an additional 340 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.